CSBio CSBio

X
[{"orgOrder":0,"company":"PharmAbcine","sponsor":"NIH","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pharm Abcine Executes of a Material Cooperative Research and Development Agreement with NIH to Evaluate Efficacy of P-403 to Treat SCLS","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Undisclosed","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"PharmAbcine"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Under this agreement, Kirk M. Druey, M.D., and colleagues at the NIAID will investigate PMC-403 in preclinical models. PharmAbcine will discuss potential clinical development in collaboration with the NIH as the study progresses.

            Lead Product(s): PMC-403

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: PMC-403

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: NIH

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement August 18, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY